Bridgewater-based Cosette Pharmaceuticals announced Feb. 20 it entered into an agreement to acquire Mayne Pharma Group Ltd. in a $430 million deal. Mayne is an Australian-headquartered specialty ...

With a $430 million buyout of Australia’s Mayne Pharma locked down, Cosette Pharmaceuticals is looking to become a leading force in women’s healthcare. The New Jersey-based drugmaker agreed to ...

BRIDGEWATER, N.J., February 20, 2025--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved ...

Cosette Pharmaceuticals Inc., a Bridgewater company that focuses on women’s health and cardiovascular medicines, announced June 8 it completed the acquisition of the global rights to Intrarosa from ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for ...

BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Cosette Pharmaceuticals, Inc., a generic pharmaceutical company primarily focused on extended topical and suppository products, announced today that it ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--#AvistaCapital--Cosette Pharma announced today that it has entered into an agreement with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) to offer CLOMID ® ...